| Literature DB >> 32033271 |
Maksymilian Gajda1, Małgorzata Kowalska1.
Abstract
BACKGROUND: Low levels of public knowledge, incorrect beliefs, and anxiety are the most often mentioned factors that may negatively affect the implementation of preventive campaigns and timely diagnosis of cancer. Cancer is a major unresolved problem for global public health. As a result, many effective preventive measures need to be found and implemented.Entities:
Keywords: anxiety; cancer; intervention; online; prevention
Mesh:
Year: 2020 PMID: 32033271 PMCID: PMC7038157 DOI: 10.3390/ijerph17030985
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Descriptive statistics of the variable assessing differences in the severity of cancer-related anxiety in the subgroups defined by the tertile distribution of Cancer Knowledge Index (CKI) value.
| Level of Cancer-Related Anxiety * | CKI Value (Baseline Survey) | ||||
|---|---|---|---|---|---|
| Overall | Low | Medium | High | ||
| 1 | 24 (5.2%) | 9 (6.3%) | 13 (7.1%) | 2 (1.4%) | 0.72 |
| 2 | 21 (4.5%) | 9 (6.3%) | 2 (1.1%) | 10 (7.2%) | |
| 3 | 57 (12.3%) | 15 (10.6%) | 18 (9.9%) | 24 (17.3%) | |
| 4 | 94 (20.3%) | 21 (14.8%) | 44 (24.2%) | 29 (20.9%) | |
| 5 | 267 (57.7%) | 88 (62.0%) | 105 (57.7%) | 74 (53.2%) | |
* 1 expresses the lowest and 5 highest levels of anxiety; ** level of statistical significance of the Cochran–Mantel–Haenszel test.
The level of cancer-related anxiety delineated by the respondents. Descriptive statistics together with differences tests in subgroups defined by selected variables.
| Level of Anxiety (5-Point Likert Scale; 1 = Lowest, 5 = Highest) | |||||||
|---|---|---|---|---|---|---|---|
| Overall | 1 | 2 | 3 | 4 | 5 |
| |
|
| |||||||
| Median (IQR) | 33 (22–47) | 42 (27.5–62) | 33 (22–56) | 35 (26–48) | 29 (20.2–46) | 33 (22–45) | 0.1 k |
|
| |||||||
| Male | 179 (38.7%) | 9 (5.0%) | 9 (5.0%) | 19 (10.6%) | 42 (23.5%) | 100 (55.9%) | 0.93 & |
| Female | 284 (61.3%) | 15 (5.3%) | 12 (4.2%) | 38 (13.4%) | 52 (18.3%) | 167 (58.8%) | |
|
| |||||||
| ≤100,000 | 218 (47.1%) | 9 (4.1%) | 8 (3.7%) | 26 (11.9%) | 45 (20.6%) | 130 (59.6%) | 0.2 & |
| >100,000 | 245 (52.9%) | 15 (6.1%) | 13 (5.3%) | 31 (12.7%) | 49 (20.0%) | 137 (55.9%) | |
|
| |||||||
| Lower | 196 (42.3%) | 9 (4.6%) | 7 (3.6%) | 24 (12.2%) | 39 (19.9%) | 117 (59.7%) | 0.35 & |
| Higher | 267 (57.7%) | 15 (5.6%) | 14 (5.2%) | 33 (12.4%) | 55 (20.6%) | 150 (56.2%) | |
|
| |||||||
| Nonmedical | 388 (83.8%) | 23 (5.9%) | 16 (4.1%) | 51 (13.1%) | 78 (20.1%) | 220 (56.7%) | 0.17 & |
| Medical | 75 (16.2%) | 1 (1.3%) | 5 (6.7%) | 6 (8.0%) | 16 (21.3%) | 47 (62.7%) | |
|
| |||||||
| No | 120 (25.9%) | 15 (12.5%) | 4 (3.3%) | 19 (15.8%) | 25 (20.8%) | 57 (47.5%) | < 0.001 & |
| Yes | 343 (74.1%) | 9 (2.6%) | 17 (5.0%) | 38 (11.1%) | 69 (20.1%) | 210 (61.2%) | |
|
| |||||||
| No | 413 (89.2%) | 18 (4.4%) | 19 (4.6%) | 47 (11.4%) | 87 (21.1%) | 242 (58.6%) | 0.02 & |
| Yes | 50 (10.8%) | 6 (12.0%) | 2 (4.0%) | 10 (20.0%) | 7 (14.0%) | 25 (50.0%) | |
|
| |||||||
| No | 415 (89.6%) | 18 (4.3%) | 19 (4.6%) | 46 (11.1%) | 90 (21.7%) | 242 (58.3%) | 0.017 & |
| Yes | 48 (10.4%) | 6 (12.5%) | 2 (4.2%) | 11 (22.9%) | 4 (8.3%) | 25 (52.1%) | |
|
| |||||||
| No | 362 (78.2%) | 17 (4.7%) | 16 (4.4%) | 42 (11.6%) | 71 (19.6%) | 216 (59.7%) | 0.12 & |
| Yes | 101 (21.8%) | 7 (6.9%) | 5 (5.0%) | 15 (14.9%) | 23 (22.8%) | 51 (50.5%) | |
|
| |||||||
| No | 35 (7.6%) | 2 (5.7%) | 2 (5.7%) | 7 (20.0%) | 6 (17.1%) | 18 (51.4%) | 0.34 & |
| Yes | 428 (92.4%) | 22 (5.1%) | 19 (4.4%) | 50 (11.7%) | 88 (20.6%) | 249 (58.2%) | |
Note: IQR, interquartile range; k, Kruskal–Wallis test; &, Cochran–Mantel–Haenszel test (nonzero correlation); * Villages and cities having ≤100,000 inhabitants were combined to ≤100,000 category; ** Primary and secondary values were combined to form a single ‘low’ category, whereas both high school and high school medical were assigned to a ‘high’ category.
Figure 1The level of anxiety depending on the declared burden of the individual and family history of cancer, as well as whether the subject had ever undergone oncological treatment.
Differences in the level of anxiety associated with selected diseases: baseline and final assessment in intervention and control groups in terms of numbers and percentages (in brackets).
| Level of Cancer-Related Anxiety * | Intervention | Control | ||||
|---|---|---|---|---|---|---|
| Baseline | Final | Baseline | Final | |||
| 1 | 15 (7.2%) | 11 (5.3%) | 0.03 | 9 (3.5%) | 10 (3.9%) | 0.6 |
| 2 | 12 (5.8%) | 16 (7.7%) | 9 (3.5%) | 11 (4.3%) | ||
| 3 | 23 (11.1%) | 34 (16.4%) | 34 (13.3%) | 26 (10.2%) | ||
| 4 | 41 (19.8%) | 48 (23.2%) | 53 (20.7%) | 67 (26.2%) | ||
| 5 | 116 (56.0%) | 98 (47.3%) | 151 (59.0%) | 142 (55.5%) | ||
* 1 expresses the lowest and 5 the highest level of anxiety; ** p, statistical significance in Wilcoxon test for paired variables.
Figure 2Self-declared baseline and final level of anxiety associated with cancer in intervention and control groups.